Innovation Passport Granted For CRN04777 For The Treatment Of Congenital Hyperinsulinism
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted CRN04777 an "Innovation Passport" for the
Femasys Inc. Announces Enrollment Completion For Stage 2 Study Of FemBloc For Permanent Birth Control
Femasys Inc. (NASDAQ:FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health,
Sanofi, Provention Bio Ink Co-Promotion Pact For Type 1 Diabetes Treatment Candidate
Provention Bio Inc (NASDAQ:PRVB) has entered into a co-promotion agreement with Sanofi SA (NASDAQ:SNY) to launch Provention’s lead investigational candidate, teplizumab, to delay…
Entera Bio Announces FDA Agreement For A Single Phase 3 Clinical Trial To Support An NDA For EB613 For The Treatment Of Osteoporosis
Entera Bio Ltd. (NASDAQ:ENTX), ("Entera" or the "Company") a leader in the development of orally delivered peptides and therapeutic proteins, announced today the successful conclusion of its Type C
Lilly Receives U.S. FDA Fast Track Designation For Tirzepatide For The Treatment Of Adults With Obesity, Or Overweight With Weight-related Comorbidities
Eli Lilly and Company (NYSE:LLY) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the investigation of tirzepatide for the treatment of adults with obesity, or
Ketamine for Parkinson’s Disease, PharmaTher Holdings Announces Grant of U.S. Patent To Cover It
PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM), a pharmaceutical company focused on developing novel uses and delivery forms of ketamine
Aldeyra Therapeutics Schedules Conference Call And Webcast To Announce Top-Line Results From Part 1 Of The Phase 3 GUARD Trial Of ADX-2191 In Proliferative Vitreoretinopathy October 6
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra) today announced it will host a webcast and conference call on Thursday, October 6, 2022, at 8:00 a.m. (ET) to report top-line results from Part 1 of the Phase 3
Takeda Seeks FDA Approval For Hereditary Angioedema Treatment For Younger Kids
The FDA has accepted Takeda Pharmaceutical Co Ltd’s (NYSE:TAK) supplemental marketing application for the potential expanded use of TAKHZYRO (lanadelumab-flyo) for…
Eiger BioPharma Shuns Plans For FDA Emergency Use Nod For COVID-19 Treatment
Following FDA feedback, Eiger BioPharmaceuticals Inc (NASDAQ:EIGR) will not submit an emergency use authorization (EUA) application of peginterferon lambda for mild-to-moderate COVID-19.…